Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31227244 | 1.00 | BCAT2 (0.55) | BCAT2CSNK1A1TYRO3DYRK1BGRM5 | |
| SCHEMBL4058072 | 0.84 | DHODH (0.51) | MAPTKDM4EALDH1A1TSHRNPC1 | |
| SCHEMBL7336250 | 0.84 | HTR2C (0.38) | BCAT2CSNK1A1TYRO3DYRK1BGRM5 | |
| SCHEMBL8523177 | 0.81 | BCAT2 (0.53) | BCAT2CSNK1A1TYRO3DYRK1BGRM5 | |
| SCHEMBL28603205 | 0.79 | SLC6A3 (0.53) | GRM5MAPTKDM4EALDH1A1TSHR | |
| SCHEMBL997865 | 0.79 | GRM5 (0.64) | BCAT2CSNK1A1TYRO3DYRK1BGRM5 | |
| SCHEMBL29506339 | 0.79 | GRM5 (0.64) | BCAT2CSNK1A1TYRO3DYRK1BGRM5 | |
| SCHEMBL31249988 | 0.79 | GRM5 (0.64) | BCAT2CSNK1A1TYRO3DYRK1BGRM5 | |
| SCHEMBL31249984 | 0.79 | GRM5 (0.64) | BCAT2CSNK1A1TYRO3DYRK1BGRM5 | |
| Hydrochloric Acid SCHEMBL28843225 | 0.77 | GRM5 (0.62) | BCAT2CSNK1A1TYRO3DYRK1BGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435957-A4 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3BETA PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMA (US) | 2005-04-13 | — | — | EP | claimed |
| EP-1435957-A2 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3BETA PROTEIN AND PROTEIN COMPLEXES | Vertex Pharmaceuticals Incorporated (US) | 2004-07-14 | — | — | EP | claimed |
| WO-2002088078-A2 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | claimed |
| US-20240024314-A1 | Methods of Treating Splenomegaly | TELIOS PHARMA, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-11642343-B2 | Methods of treating splenomegaly | TELIOS PHARMA, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220387434-A1 | COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR CANCER TREATMENT | QUOGUE IP HOLDINGS LLC (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220184069-A1 | METHODS OF TREATING SPLENOMEGALY | TELIOS PHARMA, INC. (US) | 2022-06-16 | — | — | US | disclosed |
| WO-2021146424-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-07-22 | — | — | WO | disclosed |
| CN-109311902-A | Substituted imidazo [1,2-b] pyridazine, substituted imidazo [1,5-b] pyridazine, related compound and their purposes in treatment medical disorder | 溶酶体治疗股份有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109311902-A | Substituted imidazo [1,2-b] pyridazine, substituted imidazo [1,5-b] pyridazine, related compound and their purposes in treatment medical disorder | 溶酶体治疗股份有限公司 | 2019-02-05 | — | — | CN | disclosed |
| WO-2015057992-A1 | BTK INHIBITORS FOR HEMATOPOIETIC MOBILIZATION | IZUMI RAQUEL (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2011038572-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-04-07 | — | — | WO | disclosed |
| WO-2003010153-A1 | N-ALKYL-N-PHENYLHYDROXYLAMINE COMPOUNDS CONTAINING METAL CHELATING GROUPS, THEIR PREPARATION AND THEIR THERAPEUTIC USES | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2003-02-06 | — | — | WO | disclosed |
| US-5086184-A | Herbicides | DOWELANCO (US) | 1992-02-04 | — | — | US | disclosed |
| US-4943634-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1990-07-24 | — | — | US | disclosed |
| US-4801718-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1989-01-31 | — | — | US | disclosed |
| US-4636243-A | HERBICIDES ISOXAZOLES | ELI LILLY AND COMPANY (US) | 1987-01-13 | — | — | US | disclosed |
| US-4515625-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1985-05-07 | — | — | US | disclosed |
| US-4411753-A | Synthesis of 6-t-alkyl-3-pyridazinones | ELI LILLY AND COMPANY (US) | 1983-10-25 | — | — | US | disclosed |
| US-4398044-A | Synthesis of acetyl-T-alkanes | ELI LILLY AND COMPANY (US) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387434-A1 | COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR CANCER TREATMENT | BTK, BCL9L, BCL9 | BCAT2 639/4885CSNK1A1 830/4885TYRO3 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.